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Background
Current standard of practice for most children with suspected genetic disease is to
undergo clinical molecular sequencing on germline-derived DNA taken from a blood
draw. While there are exceptions for known somatic genetic diseases (ex. SturgeWeber syndrome, McCune-Albright syndrome), somatic sources of DNA are not
routinely clinically tested due to the invasive nature of a skin punch biopsy and lack of
existing structures in some hospital systems for obtaining surgical tissue that might
otherwise be discarded1,2. Germline whole-exome sequencing (WES) currently has a
diagnostic yield of between 20-30% in pediatric cohorts, with germline whole-genome
sequencing (WGS) increasing this yield by 10-20%3,4– at least a small percentage of
non-diagnostic cases in these cohorts can be attributed to unidentified somatic
variation/mosaicism 5,6.
There are several uses for DNA and RNA derived from tissue as opposed to germline
specimens including:
1.
2.
3.
4.
5.
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Tissue Procurement
Since December 2019, we have obtained access to 647 tissue specimens from
patients and their enrolled relatives, representing 12.8% of our total enrolled
population. Among these are 77 fresh tissue specimens. These specimens were
derived from patients with a variety of clinical diagnoses including, but not limited to
epilepsy with focal cortical dysplasia, adolescent idiopathic scoliosis, cleft lip/palate,
spastic dystonic quadriparesis, congenital pulmonary airway malformation, and
anophthalmia.

FFPE DNA Extraction
We obtained 570 historical FFPE and FF specimens from both patients and enrolled
relatives. Sample sources included myocardium, esophagus, trachea, stomach,
colorectum, lung, kidney, skin, muscle connective tissue, brain, tumor, thymus, liver,
gallbladder, appendix, tonsil, endocrine glands, testes, ovary, and uterus. We
extracted and assessed DNA from a subset of 16 of the FFPE specimens. Total DNA
yield ranged from 19.8 ng to 1890 ng with concentration ranging from 0.66 ng/µl to 63
ng/µl. Average yield and concentration were 555.29 ng and 18.51 ng/µl respectively.

Functional assessment of patient genomes - Single-Cell RNA Sequencing of
Pediatric Tissue Samples
We have implemented a streamlined tissue processing protocol with downstream
sequencing and analytical workflows for single-cell (RNA) sequencing using the 10X
Genomics platform. Cells with an average of 80% cell viability are captured after
passing 40um cell strainer (to remove debris) using the 10X Genomics Chromium
Next GEM procedures (Single Cell 3’ GEM, v3.1).
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Buccal DNA Validation
We obtained 39 buccal swab-derived DNA samples from enrolled patients with nondiagnostic WGS. We performed WES on these samples and validated 93.8-98.5% of
known variants initially identified in germline DNA.

Identification of causative somatic genetic variants
Identification of somatic mosaicism in selected tissues
Functional validation of variants of interest
Improved variant annotation
Delineation of germline vs. acquired genetic variation in individuals with
hematological cancers

Our study seeks to develop a systematic method of routine tissue collection for genetic
studies as well as to provide broader evidence for the utility of these specimens in
clarifying genetic diagnosis.

Methods
Enrollment and Initial Testing
Patients qualified for the Genomic Answers for Kids (GA4K) study if they have a
known or suspected genetic diagnosis. This criteria includes any patient who has had
or is undergoing clinical genetic testing for any reason, as well as those with confirmed
diagnostic genetic testing (Tier 1). In addition, a subset of patients not undergoing
testing, but with a condition known to have possible genetic causes, such as autism,
also qualified. Patients with multifactorial diseases with known genetic contribution
such as asthma, morbid obesity, type 1 diabetes, and scoliosis were also enrolled into
the study as part of “Tier 2” cohorts. When available, parents and other relatives (both
affected and unaffected) were also enrolled. All Tier 1 patients underwent sequential
WES and whole-genome sequencing (WGS) as well as whole-genome genotyping,
single-cell RNA (scRNA-Seq) sequencing, and methylome analysis by whole-genome
bisulfite sequencing (WGBS). Tier 2 patients underwent WES and whole-genome
genotyping, with a subset also receiving scRNA-Seq. All initial studies were conducted
on germline blood DNA.
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Tissue Collection
With the assistance of information sciences, we were able to obtain a weekly report of
all patients enrolled in GA4K who were undergoing any procedure involving
anesthesia. From this, we were able to create a weekly list of possible tissuegenerating procedures. “Scavenging” of tissue removed as a routine part of the
procedure is included as part of the consenting process, as well as an additional opt-in
or opt-out question to have the surgical team remove additional tissue, providing it is
safe to do so. We developed a communication system with the operating room staff to
ensure tissue collection whenever possible on enrolled patients undergoing tissuegenerating procedures. All tissue was placed in sterile saline solution and transferred
to organ preservation medium if it could not be immediately processed. Tissue was
then routed back to the GA4K laboratory for processing, prioritizing DNA isolation for
cases without a known molecular diagnosis and RNA isolation for cases with an
existing molecular diagnosis (or both in cases were there was sufficient specimen).
Historical Specimens
In addition to fresh tissue specimens, we were able to catalogue specimen numbers
for historical pathology specimens, either formalin-fixed paraffin embedded (FFPE)
tissue, flash-frozen (FF) tissue, or both from patients and both affected and unaffected
relatives. We requested slides from a subset of these patients in order to determine
the quality and quantity of DNA obtainable from these specimens.
Buccal Specimens
We obtained buccal swabs on a subset of enrolled probands in order to validate
genetic variation between buccal swabs and germline blood samples.

Detailed assessment of patient-derived brain tissue - Advanced genome and
tissue sequencing
We assessed brain tissue from 4 unrelated patients with epilepsy, one of whom had a
known germline pathogenic variant in TSC2. Pathology from these brain specimens
showed focal cortical dysplasia (FCD). Via WGS and IsoSeq analysis, we identified a
DEPDC5 non-sense mutation as the likely cause of intractable epilepsy in one of
these patients, identifiable in both DNA and RNA from the brain specimen and not
leading to nonsense-mediated decay.
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Conclusion
Fresh tissue was the most valuable specimen source for profiling DNA and RNA
variation not identified in germline blood samples from the same patients in our cohort,
allowing both insight into personal genomic variance as well as other rare disease
genomes with the same affected tissues. As expected, yield of novel genetic
information from tissue was highly dependent upon the anatomical source of the
specimen (i.e. affected brain tissue from an epilepsy patient vs. thymus tissue
obtained incidentally from a patient with congenital heart disease). Beyond direct
impact and reclassification of Mendelian variants, the assessment of multiple
DNA/RNA sources from a patient will have the largest utility in cases of non-Mendelian
disease (such as cleft lip/palate), which constitutes a large portion of our cohort (Tier 2
populations).
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About Genomic Answers for Kids (GA4K)
Legend - Patient CMH002013-01 suffered from intractable epilepsy and in parallel to the epilepsy surgery was enrolled in the GA4K study, where brain
specimens were scavenged during surgery and blood DNA is collected routinely from proband and parents. Tissue from epilepsy surgery was dissociated fresh,
aliquoted and cryopreserved. Stored cells underwent total RNA isolation (Qiagen) where 300ng of high-quality samples (RIN>7) are used for full length cDNA
synthesis and library preparation for Isoform sequencing (Iso-SeqTM) according to protocols provided by the manufacturer (Pacific Biosciences). IsoSeq
libraries are sequenced on the Sequel RSII (PacBio) and transcripts are assembled de novo from long RNA reads (median >3kb) and aligned to GRCh38. The
parallel DNA analyses (WES and WGS) on full trio revealed a de novo frameshift mutation in DEPD5C gene (NP_001356830.1:p.Ile993PhefsTer58) in proband
as diagnostic cause for epilepsy. The IsoSeq RNA data also visualized the mutation and furthermore showed that mutant transcripts were full length. The graph
on the left shows locus transcript isoforms (annotated by GENCODE v32) on top and the transcripts sequenced in brain RNA from patient on the bottom,
showing transcript diversity resembling gene annotations in patient with no truncated transcripts, the green box shows the exon where the mutation lies. The
inset (right panel) shows the zoomed in view to the exon and mutated residue (red box) is missing in several transcripts, but clearly expressed in multiple
isoforms and ensuring that these transcripts are not subject to non-sense mediated decay (NMD).

The Genomic Answers for Kids study is led by Dr. Tomi Pastinen and funded by the Children’s
Mercy Research Institute. Our study aims to find diagnoses for children who have undergone
a lengthy diagnostic odyssey with non-diagnostic clinical testing, as well as to better
understand genetic disease as a whole. We are a multidisciplinary team of geneticists,
bioinformaticists, genetic counselors, molecular biologists, laboratory technicians, and
research coordinators. For more information you can contact us at GA4K@cmh.edu.

